177Lu Dotatate, also known as Lutathera, is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
Some key points about Lutathera's FDA-approved indications:
- Lutathera is indicated for the treatment of somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors
- It is approved for unresectable or metastatic GEP-NETs
- The FDA approval was based on the pivotal NETTER-1 phase 3 trial, which demonstrated significant improvement in progression-free survival with Lutathera compared to high-dose octreotide LAR
The National Comprehensive Cancer Network (NCCN) guidelines also recommend Lutathera as a
systemic therapy option for:
- Pancreatic neuroendocrine tumors (pNETs)
- Small bowel, colon, rectum, appendix, and metastatic NETs of unknown primary
The peptide in Lutathera,
DOTA-Tyr3-octreotate, targets
somatostatin receptors (particularly sst2) which are overexpressed in certain NETs cells. By targeting these receptors, the attached radionuclide
177Lu delivers radiation directly the tumor cells.
The
Balanced Hormone Clinic Hormone Clinic offers comprehensive cancer care for patients, including those with GEP-NETs who may be candidates for peptide receptor radionuclide therapy. Our cancer specialists will conduct a full medical evaluation to determine if targeted radionuclide therapy is an appropriate treatment option.
If eligible for
177Lu Dotatate therapy, patients undergo rigorous monitoring after each
Lutathera infusion, including bloodwork and imaging, to closely track treatment response. We also provide nutritional guidance and symptom management throughout therapy to maintain health and quality of life while fighting cancer. Contact
Balanced Hormone Clinic today to find out if you or loved one could benefit from
177Lu-Dotatate therapy administered by leading NETs experts.
In summary, key points about
FDA-approved indications for
177Lu Dotatate include:
- Unresectable or metastatic somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults
- Including foregut, midgut, hindgut NETs
- Based on pivotal NETTER-1 phase 3 trial showing improved progression-free survival
- Also recommended in NCCN guidelines for pNETs and metastatic NETs
- DOTA-Tyr3-octreotate peptide targets somatostatin receptors on NET cells
- Delivers cell-killing radiation from attached 177Lu radionuclide directly to tumors
Reach out to the experts at
Balanced Hormone Clinic Hormone Clinic to find out if targeted
177Lu Dotatate therapy is right for you or your loved one's GEP-NET.
